Evidence map›Paper›PMID 39821606›Full record

ReviewJournal of cardiovascular translational research2025

Class III Phosphatidylinositol-3 Kinase/Vacuolar Protein Sorting 34 in Cardiovascular Health and Disease.

Yuanjun Shen, Jason P Gleghorn

Abstract readReview
In one paragraph

Review in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Protein Language Models are Accidental Taxonomists.bioRxiv : the preprint server for biology · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yuanjun ShenDepartments of Biomedical Engineering, University of Delaware, Newark, DE, USA. yjshen@udel.edu.ORCID 0000-0002-8183-9531
Jason P GleghornDepartments of Biomedical Engineering, University of Delaware, Newark, DE, USA.

Funding

Mechanisms of sex differences in neonatal pulmonary oxygen toxicityR01HL144775 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI LINGAPPAN, KRITHIKA · 2019 to 2023
$2.7M
Mechanical Control of Cell Proliferation and Branching Morphogenesis in the Embryonic LungR01HL145147 · NHLBI · UNIVERSITY OF TEXAS DALLAS · PI VARNER, VICTOR D. · 2019 to 2023
$1.9M
Pressure in lung development and congenital diaphragmatic herniaR01HL133163 · NHLBI · UNIVERSITY OF DELAWARE · PI GLEGHORN, JASON PAUL · 2017 to 2021
$1.9M
Vascular Smooth Muscle Vps34 in Pulmonary Arterial HypertensionR00HL166763 · NHLBI · STATE UNIVERSITY OF NY,BINGHAMTON · PI Yuanjun Shen · 2025 to 2026
$493k
Vascular Smooth Muscle Vps34 in Pulmonary Arterial HypertensionK99HL166763 · NHLBI · UNIVERSITY OF DELAWARE · PI SHEN, YUANJUN · 2023 to 2024
$225k
American Heart Association 826806NHLBI NIH HHS K99 HL166763NHLBI NIH HHS K99HL166763NHLBI NIH HHS R00 HL166763NHLBI NIH HHS R01 HL133163NHLBI NIH HHS R01HL133163NHLBI NIH HHS R01 HL144775NHLBI NIH HHS R01HL144775NHLBI NIH HHS R01 HL145147NHLBI NIH HHS R01HL145147
6 · The paper itself

Abstract

Phosphatidylinositol-3 kinases (PI3Ks) play a critical role in maintaining cardiovascular health and the development of cardiovascular diseases (CVDs). Specifically, vacuolar Protein Sorting 34 (VPS34) or PIK3C3, the only member of Class III PI3K, plays an important role in CVD progression. The main function of VPS34 is inducing the production of phosphatidylinositol 3-phosphate, which, together with other essential structural and regulatory proteins in forming VPS34 complexes, further regulates the mammalian target of rapamycin activation, autophagy, and endocytosis. VPS34 is found to have crucial functions in the cardiovascular system, including dictating the proliferation and survival of vascular smooth muscle cells and cardiomyocytes and the formation of thrombosis. This review aims to summarize our current knowledge and recent advances in understanding the function and regulation of VPS34 in cardiovascular health and disease. We also discuss the current development of VPS34 inhibitors and their potential to treat CVDs.

Indexed as

Cardiovascular DiseasesCardiovascular SystemClass III Phosphatidylinositol 3-KinasesAnimalsAutophagyHumansMolecular Targeted TherapyPhosphoinositide-3 Kinase InhibitorsSignal TransductionClass III Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsCardiovascular diseaseCardiovascular healthVacuolar protein sorting 34

Identifiers

PMID39821606
PMCPMC12043424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.